Sanofi-sponsored Scientific Abstracts and Presentations from the American Diabetes Association (ADA) 81st Annual Scientific Sessions

A Virtual Experience

June 25-29, 2021

Insulin glargine U100/lixisenatide 33 mcg/mL

1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial

McCrimmon RJ, Home P, Cheng AY, Giorgino F, Fonseca V, Souhami E, Alvarez A, Boss AH, Melas-Melt L, Rosenstock J

95-LB: Lixilan ONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada

Hramiak I, Gerstein HC, Leiter LA, Yale JF, Bajaj H, Stewart J, Toutounji NJ, Harris S

110-LB: Efficacy, safety, and appropriateness of iGlarLixi, a fixed-ratio combination (FRC) in type 2 diabetes (T2D) in real-world settings: results from the ENSURE study

Candido R, Modugno M, Gabellieri E, Nicolucci A, Rossi M, Larosa M

118-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp: Systematic Review and Indirect Treatment Comparison (ITC)

Home P, Mehta R, Hafidh K, Gurova O, Alvarez A, Serafini P, Pourrahmat M

234-OR: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with iGlarLixi vs. Premix 70/30 in the SoliMix Trial

Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Demil N, Bonnemaire M, McCrimmon RJ, on behalf of the SoliMix Trial Investigators

364-P: Efficacy of iGlarLixi on Five-Year Risk of Diabetes-Related Complications: A Simulation Experiment

Shao H, Kianmehr H, Li P, Fonseca V, Shi L

637-P: Effectiveness of Fixed Ratio Combination of IGlarLixi in People with Type 2 Diabetes Mellitus: Experience from Routine Clinical Practice

Kis JT, Nagy G, Stella P

746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal hypoglycemia in the SoliMix trial

McCrimmon RJ, Cheng AY, Fonseca V, Choza-Romero R, Al Essa T, Alvarez A, Souhami E, Boss AH, Picard P, Rosenstock J

747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial

Polonsky WH, McCrimmon RJ, Whitmire KH, Giorgino F, Chen J, Nicholls C, Lew E, Alvarez A, Coudert M, Rosenstock J

748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe

Cheng AY, McCrimmon RJ, Fonseca V, Trescolí C, Haluzík M, Seufert J, Alvarez A, Souhami E, Picard P, Bonnemaire M, Rosenstock J

749-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe

Fonseca V, Rosenstock J, Cheng AY, Emral R, Sauque-Reyna L, Mohan V, Al Sifri SN, Alvarez A, Djaballah K, Picard P, Souhami E, McCrimmon RJ

Back to top

Insulin glargine U300

103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 100 U/mL [Gla-100]/Detemir [IDet])

Wright E, Gill J, Huse S, Li X, Reid T, Zhou FL

105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1 RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study

Bailey TS, Westerbacka J, Nicholls C, Gill J, Jones M, Shenoy L

109-LB: Comparative effectiveness of insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (iDeg-100) in insulin-naïve type 2 diabetes adults: RESTORE-2 real-world study

Fadini GP, Buzzetti R, Nicolucci A, Rossi M, Larosa M, Cucinotta D

194-OR: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Older Adults (≥70 Years) with Type 2 Diabetes (T2DM): A Subgroup Analysis of the ATOS Study

Galstyan GR, Tirosh A, Vargas-Uricoechea H, Mabunay MN, Coudert M, Pilorget V, Khan N

724-P: Factors Associated with Glycemic Control in People with Type 1 Diabetes (PWT1D) Switched to Once Daily (QD) Insulin Glargine (Gla) 300 U/ml (Gla-300): The European REALI Pooled Database

Müller-Wieland D, Gourdy P, Bonadonna RC, Freemantle N, Bigot G, Jamoul C, Ciocca A, Bonnemaire M, Mauricio D

737-P: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes Mellitus (T2DM) Uncontrolled on Basal Insulins (BI): ARTEMIS-DM Study

Sethi B, Alrubeaan K, Unubol M, Mabunay MN, Naqvi M, Berthou B, Pilorget V, Frechtel G

743-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-naïve People with Type 2 Diabetes (T2DM) and Renal Impairment (RI): A Subgroup Analysis of the ATOS Study

Tirosh A, Khan N, Vargas-Uricoechea H, Mabunay MN, Coudert M, Pilorget V, Galstyan GR

745-P: Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c

Khan N, Tirosh A, Vargas-Uricoechea H, Mabunay MN, Coudert M, Pilorget V, Galstyan GR

Back to top

Insulin glargine U100

721-P: Efficacy and Safety of Basal-First Titration Order in Patients with Type 2 Diabetes (T2D) Receiving Short-Term Intensive Insulin Therapy (SITi

Guo L, Mu Y, Wan H, Wang J, Xu B, Wang G, Jiang C, Liang L, Feng W, Liu J, Zhang X, Cui N, Yin H

730-P: Basal Insulin Regimen vs. Twice-Daily Premix Insulin Regimen After Short-Term Intensive Insulin Therapy (SIT) in Patients with Type 2 Diabetes (T2D): A Multicenter, Open-Label Randomized Controlled Trial

Mu Y, Guo L, Wan H, Wang J, Xu B, Wang G, Jiang C, Liang L, Feng W, Liu J, Zhang X, Cui N, Yin H

744-P: LIVE India: A Post-hoc Sub-Analysis of FINE-ASIA and GOAL Registries to Measure Effectiveness and Safety of Glargine 100 U/mL (Gla-100) in Insulin-Naïve Indian Adults with T2DM

Deshmukh VC, Chaudhury T, Chadha M, Chawla MS, Mukherjee S, Pitale SU, Basu D, Ghosh R, Nair A, Mohanasundaram S, Trivedi C, Salvi V, Narvekar PR, Kale S, Ramakrishnan S, Goyal G

Back to top

Diabetes management

1033-P: Complications at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Rais N, Das AK, Joshi S, Mithal A, Kalra S, Unnikrishnan A, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Kumar K

1041-P: Diabetes Complications Among Patients from Metropolitan vs. Non-Metropolitan Cities in India: One-Year Results of LANDMARC

Kalra S, Das AK, Joshi S, Mithal A, Kumar K, Unnikrishnan A, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo SK, Zargar AH, Rais N

1065-P: Glycemic Trend at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Joshi S, Das AK, Kumar K, Mithal A, Kalra S, Unnikrishnan A, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Rais N

1087-P: Therapy Trends at One Year in the Longitudinal LANDMARC Study on Real-World Outcomes in Type 2 Diabetes Patients in India

Thacker H, Das AK, Joshi S, Mithal A, Kalra S, Unnikrishnan A, Kumar K, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Rais N

1095-P: Glycemic Trend in Metropolitan vs. Non-Metropolitan Cities of India: One-Year Results of LANDMARC

Unnikrishnan A, Das AK, Joshi S, Mithal A, Kalra S, Kumar K, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Rais N

Back to top

Information is provided for scientific purposes only and may be outside the current labelling of the product. Sanofi does not recommend the use of any products in any manner inconsistent with that described in the full prescribing information. Please consult the prescribing information in your country of practice, as it can vary from country to country.

Availability of posters and/or abstracts on this site will coincide with ADA’s embargo policy.